HIV and AIDS Trial, Recruiting NCT01520844 Sponsor: ANRS, Emerging Infectious Diseases Condition: HIV and AIDS
Back to Hiv Aids

HIV and AIDS Trial, Recruiting

NCT01520844
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are infected with HIV-1 only (not also infected with HIV-2)
  • You are 18 years old or older when joining the trial
  • You are able to give written consent to participate
  • You are covered by French Social Security
  • You are willing and able to follow the requirements of the study
  • You are not currently taking antiretroviral (HIV) treatment (for most groups — see below)

The trial has four different groups, and you may qualify for one of them:

  • Group 1 (ALT): You have been HIV-1 positive for at least 8 years, have no HIV symptoms, are not on HIV treatment, and your immune cell count (CD4) has stayed above 600 and been stable or rising over the last 5 years — regardless of your virus levels
  • Group 2 (HIC): You have been HIV-1 positive for at least 5 years, have no symptoms, are not on HIV treatment, and your last 5 virus level tests have all been very low (under 400 copies/mL)
  • Group 3 (ALT HIC): You meet the conditions of both Group 1 and Group 2 combined
  • Group 4 (PTC): You previously had a high virus level, took HIV treatment for at least 12 months, then stopped treatment, and your virus levels have stayed very low (under 400 copies/mL) for at least 12 months after stopping — with at most one brief temporary rise in between (confirm with trial site)

Who may not be able to join:

  • You are currently under a court-ordered legal protection measure (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Olivier Lambotte, Professor, Kremlin Bicetre

Phone: 01 49 59 67 54

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
ANRS, Emerging Infectious Diseases
Registry
ClinicalTrials.gov
Start date
1 February 2012
Est. completion
1 September 2029

Where this trial is recruiting

🇫🇷 France

Primary endpoints

clinical and immuno-virological

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov